Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001797546 | SCV002039134 | uncertain significance | not provided | 2021-06-18 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 27535533) |
Fulgent Genetics, |
RCV002489843 | SCV002780317 | uncertain significance | Usher syndrome type 2C; Febrile seizures, familial, 4 | 2021-07-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001797546 | SCV004314678 | benign | not provided | 2024-01-13 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004616780 | SCV005117041 | uncertain significance | Inborn genetic diseases | 2024-06-17 | criteria provided, single submitter | clinical testing | The c.7030G>T (p.A2344S) alteration is located in exon 32 (coding exon 32) of the ADGRV1 gene. This alteration results from a G to T substitution at nucleotide position 7030, causing the alanine (A) at amino acid position 2344 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |